Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

[1]  V. Thannickal,et al.  Novel Mechanisms for the Antifibrotic Action of Nintedanib. , 2016, American journal of respiratory cell and molecular biology.

[2]  F. Reichenberger,et al.  Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF , 2015, European Respiratory Journal.

[3]  N. Kaminski,et al.  FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. , 2015, American journal of respiratory and critical care medicine.

[4]  P. Spagnolo,et al.  Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. , 2015, Pharmacology and Therapeutics.

[5]  R. Kaarteenaho,et al.  Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine , 2015, European clinical respiratory journal.

[6]  W. Seeger,et al.  Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. , 2015, American journal of respiratory and critical care medicine.

[7]  M. Bando,et al.  Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis , 2014, European Respiratory Journal.

[8]  V. Poletti,et al.  Combination therapy: the future of management for idiopathic pulmonary fibrosis? , 2014, The Lancet. Respiratory medicine.

[9]  C. Vancheri,et al.  Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  Kevin J Anstrom,et al.  Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[11]  R. Kaarteenaho,et al.  Lung Cancer–Associated Myofibroblasts Reveal Distinctive Ultrastructure and Function , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  B. Ryffel,et al.  Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[13]  J. Risteli,et al.  Stromal cells can be cultured and characterized from diagnostic bronchoalveolar fluid samples obtained from patients with various types of interstitial lung diseases , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[14]  B. Crestani,et al.  Treatments for idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[15]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[16]  R. Kaarteenaho.  The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis , 2013, Respiratory Research.

[17]  E. Parra,et al.  Increased fibroblast telomerase expression precedes myofibroblast α-smooth muscle actin expression in idiopathic pulmonary fibrosis , 2012, Clinics.

[18]  R. Bloigu,et al.  Myofibroblasts in interstitial lung diseases show diverse electron microscopic and invasive features , 2012, Laboratory Investigation.

[19]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[20]  M. L. R. D. Christenson,et al.  An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management , 2012 .

[21]  H. Matsumura,et al.  Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction , 2012, Archives of Dermatological Research.

[22]  Michael J. Cronce,et al.  Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition , 2011, Proceedings of the National Academy of Sciences.

[23]  Chris J Scotton,et al.  Bleomycin revisited: towards a more representative model of IPF? , 2010, American journal of physiology. Lung cellular and molecular physiology.

[24]  H. Oku,et al.  Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. , 2008, Life sciences.

[25]  D. Warburton,et al.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? , 2008, The international journal of biochemistry & cell biology.

[26]  G J Roth,et al.  Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis , 2007, European Respiratory Journal.

[27]  G. Gabbiani,et al.  Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction , 1971, Experientia.

[28]  H. Oku,et al.  Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis , 2004, European Respiratory Journal.

[29]  S. Rennard,et al.  Platelets stimulate fibroblast-mediated contraction of collagen gels , 2003, Respiratory research.

[30]  M. Selman,et al.  Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. , 2001, American journal of respiratory cell and molecular biology.

[31]  S. Iyer,et al.  Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. , 1999, The Journal of pharmacology and experimental therapeutics.

[32]  J. McDonald,et al.  The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. , 1991, The American journal of pathology.

[33]  B. Eyden,et al.  A study of spindle cell sarcomas showing myofibroblastic differentiation. , 1991, Ultrastructural pathology.